Welcome to Genmab
As a leading international biotechnology company, we believe in the transformative power of science and technology. Science is not only our bedrock, it is our inspiration. We believe in improving the lives of patients with cancer by creating and developing innovative and differentiated antibody therapeutics that will transform the future of cancer treatment. We are Genmab.
Transforming the future of cancer treatment
Cancer presents constant challenges in our society—from advancing drug development to fulfilling the unmet medical needs of patients. At Genmab, we have an appreciation for the power of the human immune system that gives us a unique perspective on how to respond and find solutions. That’s why we are focused on harnessing the immune system’s natural ability to fight against diseases to create therapeutics that have the potential to transform how cancer is treated.
Our Technology Platforms
Pioneering the next generation of antibody platforms
With an in-depth knowledge of antibody biology, we discover, develop and select the best possible antibody products. This relentless drive to innovate and advance the process of antibody discovery has led to our proprietary antibody technologies.
Genmab receives 2021 Corporate Achievement Award
We are proud to receive the 2021 Corporate Achievement Award from CancerCare. We remain dedicated to developing novel therapies with a goal to improve the lives of people with cancer.
We turn science into medicine. We use our deep antibody expertise to create cancer therapeutics with the potential to improve patients’ lives.
We are focused on our vision of transforming the future of cancer treatment.
We aim to share relevant, accurate and timely information with our investors.
With innovations, partnerships and presentations, we are making headlines.
Our passion for innovation is driven by data and rooted in science.
We know the value of finding and being good partners.
Grants & Sponsorships
We are committed to advancing healthcare and improving patient outcomes.